Phospho-EGFR (Tyr845) Polyclonal Antibody, APC-Cy7 Conjugated
Applications
Reactivity
Predicted Reactivity
| Overview | |
| Catalog # | bs-3111R-APC-Cy7-100uL |
| Product Name | Phospho-EGFR (Tyr845) Polyclonal Antibody, APC-Cy7 Conjugated |
| Applications |
WB
FCM
|
| Reactivity | Human |
| Predicted Reactivity | Mouse, Rat, Dog, Cow, Pig, Horse, Chicken, Rabbit |
| Specifications | |
| Conjugation | APC-Cy7 |
| Host | Rabbit |
| Source | KLH conjugated synthetic phosphopeptide derived from human EGFR around the phosphorylation site of Tyr845 |
| Modification Site | Tyr845 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 1956 |
| Subcellular location | Cytoplasm, Nucleus, Secreted, Cell membrane |
| Synonyms | Epidermal growth factor receptor; p170EGFR; ERBB1; HER1; Avian erythroblastic leukemia viral verbb oncogene homolog; EGF R; EGFR; erbb 1; Erbb; Erbb1; mENA; Oncogene ERBB; Receptor tyrosine protein kinase ErbB1; Urogastrone; wa2; Wa5 |
| Background | Protein kinases are enzymes that transfer a phosphate group from a phosphate donor onto an acceptor amino acid in a substrate protein. By this basic mechanism, protein kinases mediate most of the signal transduction in eukaryotic cells, regulating cellular metabolism, transcription, cell cycle progression, cytoskeletal rearrangement and cell movement, apoptosis, and differentiation. The protein kinase family is one of the largest families of proteins in eukaryotes, classified in 8 major groups based on sequence comparison of their tyrosine (PTK) or serine/threonine (STK) kinase catalytic domains. Epidermal Growth factor receptor (EGFR) is the prototype member of the type 1 receptor tyrosine kinases. EGFR overexpression in tumors indicates poor prognosis and is observed in tumors of the head and neck, brain, bladder, stomach, breast, lung, endometrium, cervix, vulva, ovary, esophagus, stomach and in squamous cell carcinoma. |
| Application Dilution | |
| WB | 1:300-5000 |
| FCM | 1:20-100 |
Frequently asked questions
Which applications is Phospho-EGFR (Tyr845) Polyclonal Antibody, APC-Cy7 Conjugated (bs-3111R-APC-Cy7) validated for, and at what dilution?
bs-3111R-APC-Cy7 is validated for WB (1:300-5000); FCM (1:20-100). These are recommended starting dilutions; optimal dilutions should be determined by the end user.
Which species does Phospho-EGFR (Tyr845) Polyclonal Antibody, APC-Cy7 Conjugated (bs-3111R-APC-Cy7) react with?
Tested reactivity: Human. Predicted reactivity (expected from sequence homology but not yet tested): Mouse, Rat, Dog, Cow, Pig, Horse, Chicken, Rabbit.
How should bs-3111R-APC-Cy7 be stored?
Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. Storage buffer: Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
What immunogen was used to raise Phospho-EGFR (Tyr845) Polyclonal Antibody, APC-Cy7 Conjugated (bs-3111R-APC-Cy7)?
KLH conjugated synthetic phosphopeptide derived from human EGFR around the phosphorylation site of Tyr845
What are the excitation and emission wavelengths of the APC-Cy7 conjugate (bs-3111R-APC-Cy7)?
APC-Cy7 on bs-3111R-APC-Cy7: excitation / emission 650nm/780nm.